{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"60 Degrees Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"SXTP"},"Address":{"label":"Address","value":"1025 CONNECTICUT AVENUE NW,SUITE 1000, WASHINGTON, District of Columbia, 20036, United States"},"Phone":{"label":"Phone","value":"202-327-5422"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Its lead product, ARAKODA (tafenoquine), is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. The Company's pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases; new products that contain the Arakoda regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. The ARAKODA regimen of tafenoquine is in Phase II study data in patients with mild-moderate COVID-19 disease. It is also planning a clinical study to assess the utility of ARAKODA as a treatment for human babesiosis. The Company is also developing Celgosivir for the treatment of COVID-19, respiratory syncytial virus (RSV), and dengue."},"CompanyUrl":{"label":"Company Url","value":"https://www.60degreespharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Bryan Smith","title":"Chief Medical Officer"},{"name":"Geoffrey S. Dow","title":"President, Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}